The overall goal of the Imaging Core is to develop, optimize, implement, and validate quantitative, surrogate predictive biomarkers of: 1) drug target engagement, 2) the type of antitumor effect induced by a particular treatment, and 3) the response of breast cancer to treatment. The Imaging Core will offer a full range of small animal functional, anatomical, and molecular imaging techniques, including magnetic resonance, computed tomography, ultrasound, fluorescence, single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging. Breast SPORE investigators will also have access to novel probe development resources, including high-throughput, diversity-oriented synthesis capabilities suitable for identifying novel imaging compounds, as well as the resources of the state-of-the-art Vanderbilt University Research Radiochemlstry Core. Novel and established molecular imaging techniques will be offered which are specifically tailored for assessing quantitative metrics of cellular metabolism and proliferation, apoptosis, angiogenesis, receptor expression and inflammation. As in the previous funding cycle, the Imaging Core will continue to partner with other Cores in the SPORE and forge new connections with the VUIIS such that services are highly cost-effective. To provide this support to the projects, the Imaging Core has identified the following three specific alms: 1. Foster collaborations between experts in advanced, quantitative non-invasive imaging and breast cancer research. In particular, the Core will support experts in all major imaging modalities, with particular emphasis on positron emission tomography (PET) and magnetic resonance imaging (MRI). 2. Develop, validate, and provide non-invasive imaging metrics of drug distribution, drug target engagement, tumor initiation, progression and treatment response for Breast SPORE investigators. 3. Provide support for analysis of quantitative imaging data, development of customized imaging protocols, including the co-registration and integration of multiple imaging modalities, histology and other in situ assays, and the development of novel imaging biomarkers.
By providing the highest quality, most rigorous assessment of breast cancer treatment response and determining which method(s) are most appropriate for clinical translation, we will be able to provide SPORE projects with imaging approaches to address basic and clinical science questions that can be readily incorporated into early clinical trials.
|Santos Guasch, Gabriela L; Beeler, J Scott; Marshall, Clayton B et al. (2018) p73 Is Required for Ovarian Follicle Development and Regulates a Gene Network Involved in Cell-to-Cell Adhesion. iScience 8:236-249|
|Croessmann, Sarah; Sheehan, Jonathan H; Lee, Kyung-Min et al. (2018) PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K? Inhibitors. Clin Cancer Res 24:1426-1435|
|Elion, David L; Cook, Rebecca S (2018) Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment. Oncotarget 9:29007-29017|
|Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21|
|Hyman, David M; Piha-Paul, Sarina A; Won, Helen et al. (2018) HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189-194|
|Luo, Na; Nixon, Mellissa J; Gonzalez-Ericsson, Paula I et al. (2018) DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun 9:248|
|Sudhan, Dhivya R; Schwarz, Luis J; Guerrero-Zotano, Angel et al. (2018) Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. Clin Cancer Res :|
|Werfel, Thomas A; Wang, Shan; Jackson, Meredith A et al. (2018) Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival. Cancer Res 78:1845-1858|
|Zhao, Shilin; Li, Chung-I; Guo, Yan et al. (2018) RnaSeqSampleSize: real data based sample size estimation for RNA sequencing. BMC Bioinformatics 19:191|
|Jia, Peilin; Zhao, Zhongming (2017) Impacts of somatic mutations on gene expression: an association perspective. Brief Bioinform 18:413-425|
Showing the most recent 10 out of 341 publications